A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This Phase 3 study is intended to provide evidence of the efficacy and safety of CP 690,550
when dosed 5 mg and 10 mg twice a day as monotherapy in adult patients with moderate to
severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in
improving signs and symptoms and physical function that were observed in the Phase 2
Rheumatoid Arthritis studies.